Donepezil/memantine extended release

Drug Profile

Donepezil/memantine extended release

Alternative Names: ADS-8703; ADS-8704; Arimenda; donepezil HCl/memantine ER; donepezil HCl/Namenda XR®; MDX-8704; memantine ER/donepezil HCl; memantine ER/donepezil IR; Namenda XR®/donepezil HCl; Namzaric

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adamas Pharmaceuticals
  • Developer Adamas Pharmaceuticals; Allergan
  • Class Analgesics; Antidementias; Antiparkinsonians; Antispastics; Indans; Nootropics; Organic bridged compounds; Piperidines; Small molecules
  • Mechanism of Action Acetylcholinesterase inhibitors; NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Alzheimer's disease
  • No development reported Dementia

Most Recent Events

  • 22 Sep 2016 Allergan and Adamas Pharmaceuticals launch new dosage strengths of Donepezil/memantine extended release in USA
  • 19 Jul 2016 The US FDA approves expanded indication for donepezil/memantine for the treatment of patients with Alzheimer's disease (Moderate-to-severe) stabilised on donepezil monotherapy
  • 18 May 2015 Launched for Alzheimer's disease in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top